TULSA-PRO® is a medical technology designed to provide radiation-free ablation of the prostate while protecting the surrounding structures like the urethra and rectum. It offers a customizable and predictable approach to prostate ablation, allowing surgeons to define the specific volume to be treated. TULSA-PRO® has shown potential in various applications, including intermediate stage prostate cancer, localized radio-recurrent cancer (cancer that has returned after previous treatment with radiation), retention and hematuria palliation in locally advanced prostate cancer (managing urine retention and blood in urine in advanced cases), and treating the transition zone in large volume benign prostatic hyperplasia (BPH) cases. The technology has received the CE mark, indicating compliance with European health, safety, and environmental protection standards, and it has also obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) in August 2019. This clearance allows TULSA-PRO® to be marketed and used in the United States.